Cara Therapeutics Inc
NASDAQ:CARA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cara Therapeutics Inc
Operating Expenses
Cara Therapeutics Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cara Therapeutics Inc
NASDAQ:CARA
|
Operating Expenses
-$59.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-11%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$38.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$17.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$27.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$26.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$24.4B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-8%
|
|
Cara Therapeutics Inc
Glance View
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.
See Also
What is Cara Therapeutics Inc's Operating Expenses?
Operating Expenses
-59.3m
USD
Based on the financial report for Dec 31, 2024, Cara Therapeutics Inc's Operating Expenses amounts to -59.3m USD.
What is Cara Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-11%
Over the last year, the Operating Expenses growth was 56%. The average annual Operating Expenses growth rates for Cara Therapeutics Inc have been 19% over the past three years , 15% over the past five years , and -11% over the past ten years .
